NLRP3 and metabolic dysfunction-associated steatotic liver disease: Zhu et al., 2018 [13] performed experiments to probe whether liraglutide is of benefit in high-fat diet-evoked murine non-alcoholic fatty liver disease (NAFLD) via repression of the hepatic NLRP3 inflammasome.